Awards

Australian CRO of the Year 2008 Frost & Sullivan

Novotech, the largest Australian owned contract research organization (CRO) has confirmed its position as the pre-eminent Australian based CRO with the award by leading industry analyst house Frost & Sullivan as the Australian CRO of the Year. The award is part of the prestigious Excellence in Healthcare Awards series covering a spectrum of healthcare practice areas in the Asia Pacific region.

International Standards Organisation (ISO)

Novotech is one of the few organisations in the industry that have secured accreditation with the International Standards Organisation (ISO). As a result of our continued successful external Audits – Novotech is a fully Quality Endorsed Company compliant to the ISO9001:2000 standard.

Asian CRO of the Year & winner Deloitte Fast 500 Asia Pacific 2006

Novotech is the recipient of the Frost & Sullivan Asian CRO of the Year 2006 – Australia Award and a winner of the Deloitte Fast 500 Asia Pacific 2006 program.

According to Frost & Sullivan Program Manager Shruti Dwivedi, Novotech demonstrated “exemplary growth and performance” and is well placed to benefit from the 15% per annum increase in trials conducted in Australia, much of which is coming from large pharmaceutical firms.

Novotech came out on top against its competitors after being evaluated on key criteria including “research capabilities, breadth and depth of services, geographical coverage, and alliances/partnerships that would enhance capabilities and the growth strategies adopted in pursuit of corporate objectives”, said Dwivedi.

“Novotech offers a broad spectrum of services in Australia and New Zealand, catered by a strong research team, experienced in diverse therapeutic fields. It has formed a subsidiary in UK as well as external partnerships/alliances in North America and other regions to widen its geographical reach.”

Novotech also won praise for its therapeutic experience with its special focus on Oncology, Ophthalmology and Cardiology trials. It conducts approximately 40 clinical trials every year, where nearly 80% are in Phase II & III, with remaining in Phase 1.